Develops cannabinoid-based therapies for ocular diseases, focusing on innovative treatments for eye disorders.
Skye Bioscience, Inc., operating in the clinical stage of biopharmaceuticals, focuses on the discovery, development, and commercialization of therapeutic drugs that modulate the endocannabinoid system, a critical regulatory network in the body.
The company's primary clinical endeavor is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting the human cannabinoid receptor 1 (CB1). Nimacimab is currently undergoing Phase II clinical trials as a subcutaneously injectable treatment for metabolic disorders, with a specific focus on addressing obesity.
Skye Bioscience is also advancing SBI-100 Ophthalmic Emulsion, a CB1 agonist undergoing Phase II clinical trials for the treatment of glaucoma and ocular hypertension. In its pursuit of innovation, the company has established strategic partnerships, including a licensing agreement with Tautomer Bioscience, (Pty) Limited, for the development and commercialization of SBI-100, as well as a collaborative research agreement with VivaCell Biotechnology Espana, S.L.U., aimed at advancing SBI-200 and exploring novel derivatives through preclinical development services. Originally named Emerald Bioscience, Inc., the company rebranded as Skye Bioscience, Inc. in January 2021, and is headquartered in San Diego, California.